Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Jaguar Health, Inc. (NASDAQ: JAGX) has announced statistically significant results for crofelemer in adult breast cancer patients from its Phase 3 OnTarget trial. The subset included nearly 180 of the 287 participants in this trial, aimed at preventing therapy-related diarrhea in adults with solid tumors.

Lisa Conte, Jaguar's president and CEO, stated that the breast cancer results were part of a responder analysis, akin to the primary endpoint in the phase 3 ADVENT trial for crofelemer. The data has been submitted to an oncology conference, and a full study report is expected in a peer-reviewed journal. Ongoing analyses of other subgroups from the OnTarget trial may lead to further submissions.

The OnTarget study's initial results did not meet its primary estimand for all tumor types. However, the subgroup analysis in breast cancer patients showed clinically meaningful improvement, suggesting better adherence to cancer therapies.

Conte also highlighted crofelemer's benefits for irritable bowel syndrome and chronic idiopathic diarrhea, to be presented at the American College of Gastroenterology Annual Scientific Meeting in October 2024.